NeuroSense Therapeutics Ltd. (NRSN) stock
NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.37−0.14 (-9.27%)
Close on Nov 18, 2026Market cap $2.52MP/E –Yield –
NeuroSense Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $6.23M, up 9.3% from the year before. The highest annual figure on record is $7.27M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.23M | +9.3% |
| FY2024 | Dec 31, 2024 | $5.70M | -21.7% |
| FY2023 | Dec 31, 2023 | $7.27M | +30.2% |
| FY2022 | Dec 31, 2022 | $5.59M | +300.8% |
| FY2021 | Dec 31, 2021 | $1.39M | – |
See a number that looks wrong?